Levodopa/Carbidopa/Entacapon Rivopharm (Carbidopa, Entacapone, Levodopa)

The combination works on three levels: Levodopa is converted to dopamine in the brain, restoring deficient neurotransmission. Carbidopa blocks peripheral conversion of levodopa, increasing the amount that reaches the central nervous system. Entacapone inhibits the COMT enzyme, slowing levodopa breakdown and extending its therapeutic effect.

Dosing is individualized. The prescribing clinician determines the appropriate strength and frequency based on the patient’s disease stage, response to therapy, and tolerability. Patients should follow the exact regimen provided by their healthcare professional and not adjust the dose on their own.

Safety data are limited. The medication should be used in pregnancy or while breastfeeding only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians typically advise a careful risk‑benefit assessment before prescribing.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Standard levodopa/carbidopa provides dopamine replacement but has a shorter plasma half‑life, leading to more frequent "off" periods. Adding entacapone (as in this combination) inhibits COMT, prolonging levodopa’s effect, reducing dosing frequency, and often improving motor control compared with levodopa/carbidopa alone.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and ensure the package is tightly closed to maintain stability throughout its shelf life.

The medication is taken orally, usually with a glass of water. It can be taken with or without food, but a consistent approach (with meals or without) helps maintain stable absorption. Tablets should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include dyskinesia (involuntary movements), hallucinations or psychosis, severe orthostatic hypotension, and rare but potentially life‑threatening reactions such as neuroleptic malignant syndrome or severe allergic responses. Patients should be monitored closely for these events, especially during treatment initiation or dose changes.

The combination is contraindicated in individuals with known hypersensitivity to levodopa, carbidopa, entacapone, or any excipients. It should also be avoided in patients with narrow‑angle glaucoma, severe hepatic impairment, or those taking non‑selective MAO inhibitors. Clinicians must review medical history before prescribing.